157 related articles for article (PubMed ID: 6231750)
21. Specific killing of human T-leukemia cells by immunotoxins prepared with ricin A chain and monoclonal anti-human T-cell leukemia antibodies.
Seon BK
Cancer Res; 1984 Jan; 44(1):259-64. PubMed ID: 6606488
[TBL] [Abstract][Full Text] [Related]
22. Selective killing of target cells by antibody-ricin A chain or antibody-gelonin hybrid molecules: comparison of cytotoxic potency and use in immunoselection procedures.
Colombatti M; Nabholz M; Gros O; Bron C
J Immunol; 1983 Dec; 131(6):3091-5. PubMed ID: 6139402
[TBL] [Abstract][Full Text] [Related]
23. Use of multiple T cell-directed intact ricin immunotoxins for autologous bone marrow transplantation.
Stong RC; Uckun F; Youle RJ; Kersey JH; Vallera DA
Blood; 1985 Sep; 66(3):627-35. PubMed ID: 3896347
[TBL] [Abstract][Full Text] [Related]
24. Antibody-ricin conjugates: a method of linkage which blocks the galactose binding site of ricin.
Foxwell BM; Ross WC; Thorpe PE
Behring Inst Mitt; 1984 May; (74):101-7. PubMed ID: 6477350
[TBL] [Abstract][Full Text] [Related]
25. A flexible peptide spacer increases the efficacy of holoricin anti-T cell immunotoxins.
Marsh JW; Neville DM
J Immunol; 1988 May; 140(10):3674-8. PubMed ID: 2896212
[TBL] [Abstract][Full Text] [Related]
26. Kinetics of protein synthesis inactivation in human T-lymphocytes by selective monoclonal antibody-ricin conjugates.
Leonard JE; Wang QC; Kaplan NO; Royston I
Cancer Res; 1985 Nov; 45(11 Pt 1):5263-9. PubMed ID: 3876881
[TBL] [Abstract][Full Text] [Related]
27. Sensitivity of target cells to immunotoxins: possible role of cell-surface antigens.
Colombatti M; Bron C
Immunology; 1985 Jun; 55(2):331-8. PubMed ID: 2861156
[TBL] [Abstract][Full Text] [Related]
28. Anti-CD6-blocked ricin: an anti-pan T-cell immunotoxin.
Collinson AR; Lambert JM; Liu Y; O'Dea C; Shah SA; Rasmussen RA; Goldmacher VS
Int J Immunopharmacol; 1994 Jan; 16(1):37-49. PubMed ID: 8150554
[TBL] [Abstract][Full Text] [Related]
29. [Selective cytotoxicity of antibody-ricin-A-chain conjugate for human tumor B cells. II. Comparison of activity of immunotoxins conjugated with poly- and monoclonal antibodies].
Tonevitskiĭ AG; Zhukova OS; Rakhmanova VA; Arsen'eva EL; Bogacheva GT
Mol Biol (Mosk); 1988; 22(4):911-6. PubMed ID: 3141780
[TBL] [Abstract][Full Text] [Related]
30. High toxic efficiency of ricin immunotoxins specific for the T-cell antigen receptor of a human leukemia T-cell line.
Izquierdo M; Balboa MA; Lamana ML; López-Botet M
Int J Cancer; 1989 Apr; 43(4):697-702. PubMed ID: 2467887
[TBL] [Abstract][Full Text] [Related]
31. Anti-CD2 (T, p50) intact ricin immunotoxins for GVHD-prophylaxis in allogeneic bone marrow transplantation.
Uckun FM; Azemove SM; Myers DE; Vallera DA
Leuk Res; 1986; 10(2):145-53. PubMed ID: 3512922
[TBL] [Abstract][Full Text] [Related]
32. Intratumour therapy of solid tumours with ricin-antibody conjugates.
Kanellos J; McKenzie IF; Pietersz GA
Immunol Cell Biol; 1989 Apr; 67 ( Pt 2)():89-99. PubMed ID: 2786496
[TBL] [Abstract][Full Text] [Related]
33. Monoclonal antibody-ricin conjugate cytotoxic to cells expressing the common acute lymphoblastic leukemia antigen (CALLA).
Pelham JM; Meyer BF; Herrmann RP; Davis RE; Raphael CL; Kraft N; Atkins RC
Pathology; 1987 Apr; 19(2):124-30. PubMed ID: 2969499
[TBL] [Abstract][Full Text] [Related]
34. Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model.
Weil-Hillman G; Runge W; Jansen FK; Vallera DA
Cancer Res; 1985 Mar; 45(3):1328-36. PubMed ID: 3971376
[TBL] [Abstract][Full Text] [Related]
35. Monoclonal antibody toxin conjugates for experimental graft-versus-host disease prophylaxis. Reagents selectively reactive with T cells and not murine stem cells.
Vallera DA; Youle RJ; Neville DM; Soderling CC; Kersey JH
Transplantation; 1983 Jul; 36(1):73-80. PubMed ID: 6346616
[No Abstract] [Full Text] [Related]
36. Cytotoxic effect of ricin A-chain conjugates containing monoclonal antibodies against human erythroid cells.
Tonevitsky AG; Agapov II; Ershova GV; Sarma T; Toptygin AYu ; Mechetner EB
Int J Immunopharmacol; 1993 Feb; 15(2):229-35. PubMed ID: 8468120
[TBL] [Abstract][Full Text] [Related]
37. Adult T cell leukemia: a potential target for ricin A chain immunotoxins.
Krönke M; Depper JM; Leonard WJ; Vitetta ES; Waldmann TA; Greene WC
Blood; 1985 Jun; 65(6):1416-21. PubMed ID: 2986744
[TBL] [Abstract][Full Text] [Related]
38. Identification and characterization of a monoclonal antibody recognizing a galactose-binding domain of the toxin ricin.
Colombatti M; Johnson VG; Skopicki HA; Fendley B; Lewis MS; Youle RJ
J Immunol; 1987 May; 138(10):3339-44. PubMed ID: 2437188
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
[TBL] [Abstract][Full Text] [Related]
40. Specific killing of lymphocytes that cause experimental autoimmune myasthenia gravis by ricin toxin-acetylcholine receptor conjugates.
Killen JA; Lindstrom JM
J Immunol; 1984 Nov; 133(5):2549-53. PubMed ID: 6332854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
